Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Takeda Pharmaceutical Company Limited”

1,022 pharma patents match "Takeda Pharmaceutical Company Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,022
Index total 30,257
Page 5 / 43

Quick answer

This filtered view shows 1,022 pharmaceutical patents matching "Takeda Pharmaceutical Company Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,022 results for “Takeda Pharmaceutical Company Limited” · 30,257 patents in full index Clear search

  1. US 11958845

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  2. US 11957684

    Treatment of heavy menstrual bleeding associated with uterine fibroids

    Takeda Pharmaceutical Company Limited · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  3. US 11958850

    Heteroaryl compounds for kinase inhibition

    Takeda Pharmaceutical Company Limited · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  4. US 11957867

    Syringe stabilizer

    Takeda Pharmaceutical Company Limited · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  5. US 11952344

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  6. US 11939327

    Heterocyclic compounds

    Takeda Pharmaceutical Company Limited · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  7. US 11938174

    Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

    Takeda Pharmaceutical Company Limited · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  8. US 11905285

    Inhibitors of plasma kallikrein and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  9. US 11897879

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  10. US 11892450

    Evaluation, assays and treatment of pKal-mediated disorders

    Takeda Pharmaceutical Company Limited · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  11. US 11884731

    Vedolizumab for the treatment of fistulizing Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  12. US 11884945

    Methods for purification of arylsulfatase A

    Takeda Pharmaceutical Company Limited · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  13. US 11857575

    Mesenchymal stem cell-derived exosomes and their uses

    Takeda Pharmaceutical Company Limited · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  14. US 11851481

    Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

    Takeda Pharmaceutical Company Limited · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  15. US 11851449

    Heterocyclic amide compounds having an RORvt inhibitory action

    Takeda Pharmaceutical Company Limited · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  16. US 11834409

    Heterocyclic NMDA antagonists

    Takeda Pharmaceutical Company Limited · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  17. US 11827601

    Heterocyclic NMDA antagonists

    Takeda Pharmaceutical Company Limited · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  18. US 11815516

    Protein biomarkers for diseases associated with the contact activation system

    Takeda Pharmaceutical Company Limited · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  19. US 11793812

    Methods of treating endometriosis

    Takeda Pharmaceutical Company Limited · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  20. US 11793855

    TFPI inhibitors and methods of use

    Takeda Pharmaceutical Company Limited · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  21. US 11795216

    Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics

    Takeda Pharmaceutical Company Limited · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  22. US 11787796

    Plasma Kallikrein inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  23. US 11786608

    Isoquinolinyl triazolone complexes

    Takeda Pharmaceutical Company Limited · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  24. US 11779635

    Subcutaneous administration of ADAMTS13

    Takeda Pharmaceutical Company Limited · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted